Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7892.018 | 1.0692 | 1.0545 | 2.4903 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7892.018 | 1.0552 | 1.0436 | 2.4903 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7892.018 | 0.9695 | 0.9753 | 2.4903 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7892.018 | 0.9444 | 0.9545 | 2.4903 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7892.018 | 0.8049 | 0.8331 | 2.4903 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7893.042 | 0.8032 | 0.8167 | 2.2789 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7893.042 | 0.8376 | 0.8504 | 2.2789 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7893.042 | 1.0310 | 1.0270 | 2.2789 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7893.042 | 0.9719 | 0.9751 | 2.2789 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7893.042 | 0.9367 | 0.9434 | 2.2789 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7893.042 | 1.0014 | 1.0013 | 2.2789 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7893.042 | 0.9936 | 0.9944 | 2.2789 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7893.042 | 0.8896 | 0.9000 | 2.2789 | |
| MDA-MB-231 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7893.042 | 0.7327 | 0.7448 | 2.2789 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7895.018 | 1.0127 | 1.0196 | 1.2916 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7895.018 | 0.9110 | 0.8608 | 1.2916 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7895.018 | 0.9788 | 0.9670 | 1.2916 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7895.018 | 1.0008 | 1.0013 | 1.2916 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7895.018 | 0.9774 | 0.9649 | 1.2916 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7895.018 | 0.9808 | 0.9702 | 1.2916 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7895.018 | 0.9976 | 0.9962 | 1.2916 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 7895.018 | 1.0381 | 1.0588 | 1.2916 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.685 | uM | 7895.018 | 0.9843 | 0.9756 | 1.2916 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7896.042 | 1.0545 | 1.0933 | 1.1632 | |
| MDA-MB-361 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7896.042 | 1.0622 | 1.1065 | 1.1632 |